Abstract
Deregulated expression of MYC contributes to the genesis of multiple human tumours. The encoded protein, MYC, functions through the transcriptional regulation of large numbers of target genes. Recent publications show that MYC is closely involved in DNA replication and the checkpoint processes that monitor progress through the S phase, and suggest that limiting replication stress is a key function of this protein. These findings could have considerable implications for our understanding of how MYC transforms cells and which mechanisms protect normal cells from transformation by activated oncogenes.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Eilers, M. & Eisenman, R. N. Myc's broad reach. Genes Dev. 22, 2755–2766 (2008).
Cairo, S. et al. Hepatic stem-like phenotype and interplay of Wnt/β-catenin and Myc signalling in aggressive childhood liver cancer. Cancer Cell 14, 471–484 (2008).
Ellwood-Yen, K. et al. Myc-driven murine prostate cancer shares molecular features with human prostate tumours. Cancer Cell 4, 223–238 (2003).
Eilers, M., Schirm, S. & Bishop, J. M. The MYC protein activates transcription of the α-prothymosin gene. EMBO J. 10, 133–141 (1991).
Vafa, O. et al. c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function. A mechanism for oncogene-induced genetic instability. Mol. Cell 9, 1031–1044 (2002).
Canman, C. E. et al. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science 281, 1677–1679 (1998).
Banin, S. et al. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 281, 1674–1677 (1998).
Felsher, D. W., Zetterberg, A., Zhu, J., Tlsty, T. & Bishop, J. M. Overexpression of MYC causes p53-dependent G2 arrest of normal fibroblasts. Proc. Natl Acad. Sci. USA 97, 10544–10548 (2000).
Felsher, D. W. & Bishop, J. M. Transient excess of MYC activity can elicit genomic instability and tumorigenesis. Proc. Natl Acad. Sci. USA 96, 3940–3944 (1999).
Mushinski, J. F. et al. Myc-induced cyclin D2 genomic instability in murine B cell neoplasms. Curr. Top. Microbiol. Immunol. 246, 183–189 (1999).
Maclean, K. H., Kastan, M. B. & Cleveland, J. L. Atm deficiency affects both apoptosis and proliferation to augment Myc-induced lymphomagenesis. Mol. Cancer Res. 5, 705–711 (2007).
Pusapati, R. V. et al. ATM promotes apoptosis and suppresses tumorigenesis in response to Myc. Proc. Natl Acad. Sci. USA 103, 1446–1451 (2006).
Reimann, M. et al. The Myc-evoked DNA damage response accounts for treatment resistance in primary lymphomas in vivo. Blood 110, 2996–3004 (2007).
Gorrini, C. et al. Tip60 is a haplo-insufficient tumour suppressor required for an oncogene-induced DNA damage response. Nature 448, 1063–1067 (2007).
Shreeram, S. et al. Regulation of ATM/p53-dependent suppression of myc-induced lymphomas by Wip1 phosphatase. J. Exp. Med. 203, 2793–2799 (2006).
Dang, C. V., Li, F. & Lee, L. A. Could MYC induction of mitochondrial biogenesis be linked to ROS production and genomic instability? Cell Cycle 4, 1465–1466 (2005).
Li, F. et al. Myc stimulates nuclearly encoded mitochondrial genes and mitochondrial biogenesis. Mol. Cell. Biol. 25, 6225–6234 (2005).
Morrish, F. & Hockenbery, D. Myc's mastery of mitochondrial mischief. Cell Cycle 2, 11–13 (2003).
Ray, S. et al. MYC can induce DNA breaks in vivo and in vitro independent of reactive oxygen species. Cancer Res. 66, 6598–6605 (2006).
Tanaka, H. et al. E2F1 and c-Myc potentiate apoptosis through inhibition of NF-κB activity that facilitates MnSOD-mediated ROS elimination. Mol. Cell 9, 1017–1029 (2002).
Gao, P. et al. HIF-dependent antitumorigenic effect of antioxidants in vivo. Cancer Cell 12, 230–238 (2007).
Gordan, J. D., Bertout, J. A., Hu, C. J., Diehl, J. A. & Simon, M. C. HIF-2α promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity. Cancer Cell 11, 335–347 (2007).
Gordan, J. D. et al. HIF-α effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell 14, 435–446 (2008).
Menssen, A. & Hermeking, H. Characterization of the c-MYC-regulated transcriptome by SAGE: identification and analysis of c-MYC target genes. Proc. Natl Acad. Sci. USA 99, 6274–6279 (2002).
Li, Z. et al. A global transcriptional regulatory role for c-Myc in Burkitt's lymphoma cells. Proc. Natl Acad. Sci. USA 100, 8164–8169 (2003).
Britton, S., Salles, B. & Calsou, P. c-MYC protein is degraded in response to UV irradiation. Cell Cycle 7, 63–70 (2008).
Herold, S. et al. Miz1 and HectH9 regulate the stability of the checkpoint protein, TopBP1. EMBO J. 27, 2851–2861 (2008).
Herold, S. et al. Negative regulation of the mammalian UV response by Myc through association with Miz-1. Mol. Cell 10, 509–521 (2002).
Seoane, J., Le, H. V. & Massague, J. Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature 419, 729–734 (2002).
Kumagai, A., Lee, J., Yoo, H. Y. & Dunphy, W. G. TopBP1 activates the ATR–ATRIP complex. Cell 124, 943–955 (2006).
Dominguez-Sola, D. et al. Non-transcriptional control of DNA replication by c-Myc. Nature 448, 445–451 (2007).
Shechter, D., Costanzo, V. & Gautier, J. ATR and ATM regulate the timing of DNA replication origin firing. Nature Cell Biol. 6, 648–655 (2004).
Pickering, M. T., Stadler, B. M. & Kowalik, T. F. miR-17 and miR-20a temper an E2F1-induced G1 checkpoint to regulate cell cycle progression. Oncogene 28, 140–145 (2009).
Steiner, P. et al. Identification of a Myc-dependent step during the formation of active G1 cyclin/cdk complexes. EMBO J. 14, 4814–4826 (1995).
Vlach, J., Hennecke, S., Alevizopoulos, K., Conti, D. & Amati, B. Growth arrest by the cyclin-dependent kinase inhibitor p27Kip1 is abrogated by c-Myc. EMBO J. 15, 6595–6604 (1996).
Liu, Y. C. et al. Global regulation of nucleotide biosynthetic genes by c-Myc. PLoS ONE 3, e2722 (2008).
Zhao, X., Muller, E. G. & Rothstein, R. A suppressor of two essential checkpoint genes identifies a novel protein that negatively affects dNTP pools. Mol. Cell 2, 329–340 (1998).
Koshiji, M. et al. HIF-1α induces genetic instability by transcriptionally downregulating MutSα expression. Mol. Cell 17, 793–803 (2005).
Syljuasen, R. G. et al. Inhibition of human Chk1 causes increased initiation of DNA replication, phosphorylation of ATR targets, and DNA breakage. Mol. Cell. Biol. 25, 3553–3562 (2005).
Fang, Y. et al. ATR functions as a gene dosage-dependent tumour suppressor on a mismatch repair-deficient background. EMBO J. 23, 3164–3174 (2004).
Land, H., Parada, L. F. & Weinberg, R. A. Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature 304, 596–602 (1983).
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D. & Lowe, S. W. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88, 593–602 (1997).
Zhuang, D. et al. C-MYC overexpression is required for continuous suppression of oncogene-induced senescence in melanoma cells. Oncogene 27, 6623–6634 (2008).
Bartkova, J. et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 444, 633–637 (2006).
Toledo, L. I., Murga, M., Gutierrez-Martinez, P., Soria, R. & Fernandez-Capetillo, O. ATR signalling can drive cells into senescence in the absence of DNA breaks. Genes Dev. 22, 297–302 (2008).
Di Micco, R. et al. DNA damage response activation in mouse embryonic fibroblasts undergoing replicative senescence and following spontaneous immortalization. Cell Cycle 7, 3601–3606 (2008).
Acknowledgements
The work of the authors' laboratory that is described here was supported by grants from the Deutsche Forschungsgemeinschaft via Transregio 17 (“Ras-dependent pathways in human cancer”) and Research Group 531 (“Chromatin-mediated biological decisions”).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Related links
Rights and permissions
About this article
Cite this article
Herold, S., Herkert, B. & Eilers, M. Facilitating replication under stress: an oncogenic function of MYC?. Nat Rev Cancer 9, 441–444 (2009). https://doi.org/10.1038/nrc2640
Issue Date:
DOI: https://doi.org/10.1038/nrc2640
This article is cited by
-
Carbon ion irradiation-induced DNA damage evokes cell cycle arrest and apoptosis via the pRb/E2F1/c-Myc signaling pathway in p53-deficient prostate cancer PC-3 cells
Nuclear Science and Techniques (2021)
-
Tracking the expression of therapeutic protein targets in rare cells by antibody-mediated nanoparticle labelling and magnetic sorting
Nature Biomedical Engineering (2020)
-
Molecular mechanisms underlying gliomas and glioblastoma pathogenesis revealed by bioinformatics analysis of microarray data
Medical Oncology (2017)
-
MicroRNA-449a enhances radiosensitivity by downregulation of c-Myc in prostate cancer cells
Scientific Reports (2016)
-
Gastric cancer and gene copy number variation: emerging cancer drivers for targeted therapy
Oncogene (2016)